Ozanimod for treating relapsing–remitting multiple sclerosis

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers (PDF 4.86 MB)

  Published:

  09 June 2021

• Final appraisal determination committee papers (PDF 1.85 MB)

  Published:

  09 June 2021